Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Bjerre, Christina Annette; Knoop, Ann; Bjerre, Karsten; Larsen, Marthe; Henriksen, Katrine L; Lyng, Maria Bibi; Ditzel, Henrik J.; Rasmussen, Birgitte; Brünner, Nils; Ejlertsen, Bent; Lænkholm, Anne‐Vibeke

doi:10.3109/0284186x.2012.734922

Cited by 13 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They reported that a high Ki-67 value (>14%) independently predicted a poor prognosis. 13 Therefore, oncologists at Ehime University Hospital use 14% as the cutoff point for Ki-67 expression to divide ER-positive breast cancers into low-and high-proliferation groups. Fourth, the T1 and T2 relaxation times and PD acquired using synthetic MRI were not compared to those evaluated using more traditional methods.…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, the Ki-67 labelling index is known to be a valuable prognostic marker in breast cancer and can distinguish between luminal A (lower Ki-67 levels; <14%) and B (higher Ki-67 levels; !14%) subtypes. 13 Moreover, the Ki-67 index reflects the extent of proliferative activity, an indicator of tumour aggressiveness. 14 Therefore, an accurate evaluation of Ki-67 status is important for the prognostic analysis of breast cancer; however, the accuracy of traditional invasive detection methods, namely biopsies, is influenced by sampling errors as biopsies may often not be sufficient in assessing intratumoural heterogeneity expression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study

et al. 2020

View full text Add to dashboard Cite

To evaluate the utility of synthetic magnetic resonance imaging (MRI) of the breast in predicting the Ki-67 status in patients with oestrogen receptor (ER)-positive breast cancer. MATERIALS AND METHODS: Forty-nine patients with 50 histopathologically proven breast cancers who underwent additional synthetic MRI were enrolled in the present study. Using synthetic MRI images, T1 and T2 relaxation times and their standard deviations (SD) in the breast lesions before (T1-Pre, T2-Pre, PD-Pre, SD of T1-Pre, SD of T2-Pre, SD of PD-Pre) and after (T1-Gd, T2-Gd, PD-Gd, SD of T1-Gd, SD of T2-Gd, SD of PD-Gd) contrast agent injection were obtained. These quantitative values were compared between the low Ki-67 expression (<14%) lesions (low-proliferation group: n¼23) and high Ki-67 expression (!14%) lesions (high-proliferation group: n¼27). RESULTS: The univariate analysis showed that the SD of T1-Gd (p<0.001) and T2-Gd (p¼0.042) were significantly higher in the high-proliferation group than in the lowproliferation group. Multivariate analysis further showed that the SD of T1-Gd was a significant and independent predictor of Ki-67 expression, with an area under the receiver operating characteristic (AUROC) curve of 0.885. The sensitivity, specificity, and accuracy of the SD of T1-Gd with an optimal cutoff value of 98.5 were 77.8%, 87%, and 82%, respectively. CONCLUSION: The SD of T1-Gd obtained from synthetic MRI was useful to predict Ki-67 status.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…39,40 Many previous studies have already demonstrated that Ki-67 expression is the strongest individual factor associated with poor differentiation of tumors and tumor size in BC. 41,42 Numerous studies have also shown that high Ki-67 expression has a negative relationship with ER expression. 42 One study showed an inverse correlation between expression of the hormone receptors, ER and PR, and Ki-67.…”

Section: Discussionmentioning

confidence: 99%

ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis

et al. 2017

View full text Add to dashboard Cite

Breast cancer is a malignant tumor that is harmful to women's health around the world. Investigating the biological mechanism is, therefore, of pivotal importance to improve patients' prognoses. Compared to non-neoplastic tissues, enhanced glucose and lipid metabolism is one of the most common properties of malignant breast cancer. Adenosine triphosphate (ATP) citrate lyase is a key enzyme linking aerobic glycolysis and fatty acid synthesis and is of high biological and prognostic significance in breast cancer. In our clinical study, fresh clinical tissues were used to analyze ATP citrate lyase expression by western blotting, and paraffin archived samples from 62 breast cancer patients were used to analyze ATP citrate lyase expression by immunohistochemistry. In the cellular study, following small interfering RNA-mediated inhibition of ATP citrate lyase in MCF-7 cells, cell viability and apoptosis were measured using the Cell Counting Kit-8 and flow cytometry, respectively. Breast cancer tissues showed strong expression of ATP citrate lyase, whereas adjacent normal tissues showed weak expression. Silencing of endogenous ATP citrate lyase expression by small interfering RNA in MCF-7 cells suppressed cell viability and increased cell apoptosis. Collectively, our study revealed that expression of ATP citrate lyase was significantly increased in breast cancer tissue compared with normal tissue. In addition, we found that depletion of ATP citrate lyase suppressed tumor growth, which suggests that ATP citrate lyase-related inhibitors might be potential therapeutic approaches for breast cancer.

show abstract

“…Nuclear protein Ki‐67 expression increases during cell proliferation and the percentage of cells positive for Ki‐67, termed the Ki‐67 labeling index (LI), has been shown to be a prognostic factor in many cancers, including breast cancer . Ki‐67 is a useful marker of proliferation because it is weakly expressed in G 0 but more strongly expressed in proliferating cells .…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have shown that the percentage of Ki‐67‐positive cells detected by immunohistochemical (IHC) staining of breast cancer tissue correlates with patient outcomes. For example, Ki‐67 LI has been shown to be an independent prognostic factor in patients with pathological T1N0 disease who did not receive postoperative chemotherapy; in menopausal patients with estrogen receptor (ER)‐positive/ HER2 ‐negative breast cancer who received tamoxifen therapy without postoperative chemotherapy; and in patients with ER‐positive/ HER2 ‐negative cancer, including those who received postoperative chemotherapy . These studies stratified patients based on a Ki‐67 LI higher or lower than a pre‐specified cutoff value; the outcomes were generally better in patients with a lower LI.…”

Section: Introductionmentioning

confidence: 99%

Changes in the Ki‐67 labeling index between primary breast cancer and metachronous metastatic axillary lymph node: A retrospective observational study

et al. 2018

View full text Add to dashboard Cite

BackgroundThe Ki‐67 labeling index (LI) is a well‐known prognostic factor for primary breast cancer, but its clinical significance for metachronous axillary lymph node (ALN) recurrence has not been well documented.MethodsKi‐67 expression in primary tumors (PTs) and ALN metastases (ALNMs) was evaluated in 21 patients and quantified to investigate the relationship between Ki‐67 LIs in PTs and metachronous ALNMs.ResultsThe median Ki‐67 LIs in the PTs and ALNMs were 25.2% (range: 2.3–80.2%) and 70% (range: 10.4–97.4%), respectively. A majority of patients had higher Ki‐67 LIs in ALNMs than in PTs (76.2%, 16/21). Disease‐specific survival was significantly better in patients with a lower‐than‐median ALNM Ki‐67 LI (P = 0.019, log‐rank test). Receiver operating characteristic curves showed a PT Ki‐67 LI of 62.8% as the optimal cutoff value and an ALNM Ki‐67 LI of 65.1%. Accordingly, we divided the patients into four groups: PT Ki‐67 LI lower than 62.8%/ALNM Ki‐67 LI lower than 65.1%, PT Ki‐67 LI lower/ALNM Ki‐67 LI higher, PT Ki‐67 LI higher/ALNM Ki‐67 LI higher, and PT Ki‐67 LI higher/ALNM Ki‐67 LI lower. Disease‐specific survival was significantly better in patients with Ki‐67 LI lower/ALNM Ki‐67 LI lower than in the other groups.ConclusionThis is the first study to show that the Ki‐67 LI in metachronous ALNM is a prognostic factor for patients with metachronous ALN recurrence of breast cancer.

show abstract

Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

Cited by 13 publications

References 24 publications

Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study

Utility of synthetic MRI in predicting the Ki-67 status of oestrogen receptor-positive breast cancer: a feasibility study

ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis

Changes in the Ki‐67 labeling index between primary breast cancer and metachronous metastatic axillary lymph node: A retrospective observational study

Contact Info

Product

Resources

About